Arch Therapeutics Closes In On CE Mark For Novel Blood Control Agent
Executive Summary
Securing the CE mark for its topical hemostatic agent has taken Arch Therapeutics longer than expected, but the company now predicts filing for a CE mark by the end of 2016, and is looking for a partner to help commercialize it in Europe.
You may also be interested in...
Arch Therapeutics Targets mid-2016 For Commercial Launch Of AC5 Hemostatic Agent
Arch Therapeutics has begun enrolling a 46-patient randomized trial to support a CE mark for its AC5 topical hemostatic agent by sometime in the summer, Arch Therapeutics president and CEO Terence Norchi told Clinica.
Minute Insight: Abbott Plans Move Into Famous Chicago Skyscraper
Local newspapers in Chicago confirm that Abbott is leasing space in Chicago’s most famous building in an attempt to better serve employees who live closer to the city than its Lake County, IL, campus.
Abbott Announces Another Health Equity Initiative
The Abbott Fund, the company’s charitable foundation, has granted Easterseals $750,000 to fund a three-year pilot project supporting education and community health equity.